Systems biology based drug repositioning for development of cancer therapy

B Turanli, O Altay, J Borén, H Turkez, J Nielsen… - Seminars in cancer …, 2021 - Elsevier
Drug repositioning is a powerful method that can assists the conventional drug discovery
process by using existing drugs for treatment of a disease rather than its original indication …

Drug repositioning for effective prostate cancer treatment

B Turanli, M Grøtli, J Boren, J Nielsen, M Uhlen… - Frontiers in …, 2018 - frontiersin.org
Drug repositioning has gained attention from both academia and pharmaceutical companies
as an auxiliary process to conventional drug discovery. Chemotherapeutic agents have …

Integrative transcriptomics analysis of lung epithelial cells and identification of repurposable drug candidates for COVID-19

T Islam, MR Rahman, B Aydin, H Beklen… - European Journal of …, 2020 - Elsevier
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease, more commonly
COVID-19 has emerged as a world health pandemic. There are couples of treatment …

Discovery of potent SARS-CoV-2 inhibitors from approved antiviral drugs via docking and virtual screening

S Chtita, A Belhassan, A Aouidate… - … chemistry & high …, 2021 - ingentaconnect.com
Background: Coronavirus Disease 2019 (COVID-19) pandemic continues to threaten
patients, societies and healthcare systems around the world. There is an urgent need to …

Identification of prognostic biomarker signatures and candidate drugs in colorectal cancer: insights from systems biology analysis

MR Rahman, T Islam, E Gov, B Turanli, G Gulfidan… - Medicina, 2019 - mdpi.com
Background and objectives: Colorectal cancer (CRC) is the second most common cause of
cancer-related death in the world, but early diagnosis ameliorates the survival of CRC. This …

Repositioning of anti-inflammatory drugs for the treatment of cervical cancer sub-types

M Kori, KY Arga, A Mardinoglu, B Turanli - Frontiers in Pharmacology, 2022 - frontiersin.org
Cervical cancer is the fourth most commonly diagnosed cancer worldwide and, in almost all
cases is caused by infection with highly oncogenic Human Papillomaviruses (HPVs). On the …

Drug targeting and biomarkers in head and neck cancers: insights from systems biology analyses

T Islam, R Rahman, E Gov, B Turanli… - Omics: a journal of …, 2018 - liebertpub.com
The head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers
in the world, but robust biomarkers and diagnostics are still not available. This study …

Overcoming drug resistance in advanced prostate cancer by drug repurposing

HF Bahmad, T Demus, MM Moubarak, D Daher… - Medical …, 2022 - mdpi.com
Prostate cancer (PCa) is the second most common cancer in men. Common treatments
include active surveillance, surgery, or radiation. Androgen deprivation therapy and …

Immune cell-specific and common molecular signatures in rheumatoid arthritis through molecular network approaches

B Comertpay, E Gov - Biosystems, 2023 - Elsevier
Rheumatoid arthritis (RA) is an autoimmune disorder and common symptom of RA is chronic
synovial inflammation. The pathogenesis of RA is not fully understood. Therefore, we aimed …

Multi-omic data interpretation to repurpose subtype specific drug candidates for breast cancer

B Turanli, K Karagoz, G Bidkhori, R Sinha… - Frontiers in …, 2019 - frontiersin.org
Triple-negative breast cancer (TNBC), which is largely synonymous with the basal-like
molecular subtype, is the 5th leading cause of cancer deaths for women in the United States …